Challenges and Best Practices in Corporate AI Governance:Lessons from the Biopharmaceutical Industry
Jakob M\"okander, Margi Sheth, Mimmi Gersbro-Sundler, Peder, Blomgren, Luciano Floridi

TL;DR
This paper discusses the challenges and best practices in implementing AI governance in the biopharmaceutical industry, based on AstraZeneca's experience, offering practical guidance for organizations.
Contribution
It provides a detailed case study of AstraZeneca's approach to operationalizing AI governance, highlighting common challenges and effective strategies.
Findings
Defining the scope of AI governance is complex.
Harmonizing standards across decentralized units is challenging.
Measuring the impact of governance initiatives is essential.
Abstract
While the use of artificial intelligence (AI) systems promises to bring significant economic and social benefits, it is also coupled with ethical, legal, and technical challenges. Business leaders thus face the question of how to best reap the benefits of automation whilst managing the associated risks. As a first step, many companies have committed themselves to various sets of ethics principles aimed at guiding the design and use of AI systems. So far so good. But how can well-intentioned ethical principles be translated into effective practice? And what challenges await companies that attempt to operationalize AI governance? In this article, we address these questions by drawing on our first-hand experience of shaping and driving the roll-out of AI governance within AstraZeneca, a biopharmaceutical company. The examples we discuss highlight challenges that any organization attempting…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
MethodsFocus
